ShareValue scores for NYXH: Valuation 41, Quality 34, Growth 78, Health 38.
NYXHNASDAQ
Nyxoah
$1.31
(-7.09%)
NYXHNASDAQ
Nyxoah
$1.31(-7.09%)
Loading chart...
Sentiment
Verdicts
Value:Fair Value
Quality:Weak
Growth:Strong
Health:Stressed
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
3% to 18%
Rating
Trap Risk
Return
3% to 18%
Valuation
41
Fair Value
Price vs Value
Quality
34
Weak
Business Strength
Growth
78
Strong
Revenue & Earnings
Health
38
Stressed
Financial Stability
Momentum
29
Bearish
Price Trend
Company Details
About
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Market Cap$131M
P/E RatioN/A
Dividend YieldNone
Sector Rank#992
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026